Unity Biotechnology, Inc. (UBX)
NASDAQ: UBX · Real-Time Price · USD
0.9900
-0.0700 (-6.60%)
At close: Apr 3, 2025, 4:00 PM
0.9844
-0.0056 (-0.57%)
Pre-market: Apr 4, 2025, 7:42 AM EDT

Company Description

Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging.

Its lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy.

The company also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2048, a Tie2/VEGF bispecific; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of eye diseases; and UBX2089, a α-Klotho hormone drug candidate for multiple neurology indications.

The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015.

Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.

Unity Biotechnology, Inc.
Unity Biotechnology logo
Country United States
Founded 2009
IPO Date May 3, 2018
Industry Biotechnology
Sector Healthcare
Employees 16
CEO Anirvan Ghosh

Contact Details

Address:
285 East Grand Avenue
South San Francisco, California 94080
United States
Phone 650 416 1192
Website unitybiotechnology.com

Stock Details

Ticker Symbol UBX
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001463361
CUSIP Number 91381U101
ISIN Number US91381U2006
Employer ID 26-4726035
SIC Code 2834

Key Executives

Name Position
Dr. Anirvan Ghosh Ph.D. Chief Executive Officer and Director
Dr. Nathaniel E. David A.B., Ph.D. Co-Founder and Executive Director
Lynne Marie Sullivan CPA Chief Financial Officer and Head of Corporate Development
Alexander Hieu Nguyen J.D. Chief Legal Officer, Head of Operations and Corporate Secretary
Dr. Jan M. van Deursen Ph.D. Founder
Dr. Przemyslaw Sapieha Ph.D. Chief Scientist
Alicia Tozier M.B.A. Chief Strategy Officer
Dr. Federico Grossi M.D., Ph.D. Chief Medical Officer

Latest SEC Filings

Date Type Title
Apr 3, 2025 144 Filing
Apr 3, 2025 144 Filing
Apr 3, 2025 144 Filing
Mar 24, 2025 8-K Current Report
Mar 17, 2025 8-K Current Report
Mar 10, 2025 8-K Current Report
Mar 7, 2025 S-8 Securities to be offered to employees in employee benefit plans
Mar 7, 2025 10-K Annual Report
Mar 7, 2025 8-K Current Report
Jan 6, 2025 8-K Current Report